Chronic Inflammation and Exercise Responsiveness

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT02732509
Collaborator
(none)
146
Enrollment
1
Location
70
Duration (Months)
2.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine how chronic inflammation influences skeletal muscle protein metabolism and metabolic function in humans. The investigators will evaluate acute responsiveness to a single bout of exercise in men and women who are either lean or overweight/obese. The investigators will explore the relationship between circulating inflammatory markers and anabolic, proteomic, and transcriptional responses to acute exercise. The investigators will measure skeletal muscle protein synthesis in the postabsorptive state and in response to a single bout of exercise.

Condition or DiseaseIntervention/TreatmentPhase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    146 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Chronic Inflammation and Exercise Responsiveness
    Study Start Date :
    Mar 1, 2016
    Actual Primary Completion Date :
    Dec 31, 2021
    Actual Study Completion Date :
    Dec 31, 2021

    Arms and Interventions

    ArmIntervention/Treatment
    Lean

    Body mass index less than 25 kg/m2

    Overweight/obese

    Body mass index 25-45 kg/m2

    Outcome Measures

    Primary Outcome Measures

    1. Maximal oxygen consumption rates in mitochondria isolated from skeletal muscles [1 day]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age 30-55 years

    • BMI 19-45 kg/m2

    Exclusion Criteria:
    • Anemia (female subjects hemoglobin of <11 g/dl and male subjects hemoglobin <12 g/dl)

    • Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)

    • Renal insufficiency/failure (serum creatinine > 1.5mg/dl)

    • Oral warfarin group medications or history of blood clotting disorders.

    • Pregnancy or breastfeeding

    • Alcohol consumption greater than 2 glasses/day or other substance abuse

    • Untreated or uncontrolled thyroid disorders

    • Debilitating chronic disease (at the discretion of the investigators)

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Mayo ClinicRochesterMinnesotaUnited States55905

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Ian R Lanza, PhD, Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Ian R. Lanza, Associate Professor of Medicine, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT02732509
    Other Study ID Numbers:
    • 16-000437
    First Posted:
    Apr 8, 2016
    Last Update Posted:
    Jan 13, 2022
    Last Verified:
    Jan 1, 2022
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 13, 2022